'김갑성' 기자의 전체기사
-
Benchling Reveals the Next Chapter of R&D at Benchtalk 2025
Benchling AI debuts alongside major new capabilities for antibody discovery, automated data analysis, and development BOSTON, Oct. 14, 2025 -- Benchling today unveiled major new capabilities at Benchtalk, its annual customer conference. These new releases are designed to help biotech companies automate R&D workflows and bring the power of AI into scientists' everyday work. "At Benchling, we are on a mission to unlock the power of biotechnology. Advances in AI will help our customers get life-saving medicines to patients faster," said Sajith Wickramasekara,
- 김갑성 기자
- 2025-10-14 21:14
-
Co-PSMA trial achieves primary endpoint
SYDNEY, Oct. 14, 2025 -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT), led by Prof Louise Emmett at St Vincent's Hospital Sydney, has achieved its primary endpoint with a statistically significant higher number of prostate-specific membrane antigen (PSMA)-positive prostate cancer lesions detected using 64Cu-
- 김갑성 기자
- 2025-10-14 21:03
-
Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidne…
AI-powered histopathology demonstrates predictive value for immunotherapy outcomes in pMMR mCRC, advanced ccRCC, and NSCLC with data featured in both oral and poster presentations SEOUL, South Korea, Oct. 14, 2025 -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced the presentation of three studies at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. All three studies highlight how Lunit's AI pathology solution, Lunit SCOPE IO®, can identify biomarkers that p
- 김갑성 기자
- 2025-10-14 21:00
-
Pictor's Proteomics Platform Offers Promising Advancement for D…
New research highlights the Pictor PictVet™ Mycoplasma bovis IgG Multiplex ELISA's enhanced analytical performance through multiplexing and its potential to enhance global disease management. CARLSBAD, Calif., Oct. 14, 2025 -- Mycoplasma bovis is a devastating pathogen that threatens cattle health and productivity worldwide. In the United States alone, economic losses due to M. bovis mastitis are estimated to be above $100 million annually. While Mycoplasma bovis is not a human infection risk, it is a public health systems risk — through antimicrobial resistance, food security
- 김갑성 기자
- 2025-10-14 21:00
-
Complete Genomics Highlights New Products, Partnerships,…
BOSTON, Oct. 14, 2025 -- Complete Genomics, a leading innovator in genomic sequencing, today announced a series of milestones at the American Society of Human Genetics (ASHG) Annual Meeting, Oct. 14–18, 2025 in Boston. At ASHG 2025, for the first time, Complete Genomics will host a DNBSEQ™ User Group Meeting to bring together researchers and customers to share best practices, explore applications across oncology, rare disease and population genomics, and hear updates from the company on product innovations. The meeting will take place on Tuesday, Oct. 14, 2025, 8:30 a.m. - 5:00 p.m. ED
- 김갑성 기자
- 2025-10-14 21:00
-
India's No:1 Ranked Institute IIT Madras partners with Hyund…
CHENNAI, India, Oct. 14, 2025 -- Indian Institute of Technology Madras (IIT Madras), India's No:1 Ranked Educational Institution, is partnering with Hyundai Motor India Foundation (HMIF), the CSR arm of Hyundai Motor India Limited (HMIL), to launch 'Hyundai Hope for Cancer' - a pioneering initiative dedicated to transforming paediatric cancer care in India. As part of its multi-year commitment towards this cause, HMIF has allocated a social impact investment of INR 56 Crore towards this landmark project. HMIL is the Indian arm of the South Korean automaker Hyundai Motor
- 김갑성 기자
- 2025-10-14 20:30
-
India's No:1 Ranked Institute IIT Madras partners with Hyund…
CHENNAI, India, Oct. 14, 2025 -- Indian Institute of Technology Madras (IIT Madras), India's No:1 Ranked Educational Institution, is partnering with Hyundai Motor India Foundation (HMIF), the CSR arm of Hyundai Motor India Limited (HMIL), to launch 'Hyundai Hope for Cancer' - a pioneering initiative dedicated to transforming paediatric cancer care in India. As part of its multi-year commitment towards this cause, HMIF has allocated a social impact investment of INR 56 Crore towards this landmark project. HMIL is the Indian arm of the South Korean automaker Hyundai Motor
- 김갑성 기자
- 2025-10-14 20:30
-
Kyoto University Engineering Ph.D. Team Achieves Technolo…
[ 메디채널 김갑성 기자 ] —— Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025 CHENGDU, China, Oct. 14, 2025 -- The 2025 Chinese Biomaterials Congress recently convened in Shaoxing, Zhejiang, bringing together a prestigious gathering of leading minds in the field. Attendees included Chinese Academy of Engineering academicians Zhang Xingdong and Wang Yingjun, Chinese Academy of Sciences academicians Chen Xuesi, Tang Peifu, and Chen Chunying, alongside renowned international experts such as U.S. National Academy of Engineering member Leonar
- 김갑성 기자
- 2025-10-14 20:30
-
Asia University Partners with NucleicAI to Build a Sovereign AI Li…
TAICHUNG, Oct. 14, 2025 -- Asia University will partner with NucleicAI LLC, a next-generation platform and data company specializing in AI-driven genomics, precision medicine, and health intelligence, to build a Sovereign AI Life Science Data Platform in Taiwan. The platform will be hosted in-country, supporting secure data sharing, advanced analytics, and research collaboration while preserving data sovereignty. The signing of the Memorandum of Understanding took place at the IEEE International Conference on AI × Medicine, Health, and Care in Taichung, featuring a keynot
- 김갑성 기자
- 2025-10-14 20:00
-
Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance…
SHANGHAI, Oct. 14, 2025 -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the National Medical Products Administration (NMPA) in China to initiate clinical study in patients with advanced solid tumors. 7MW4911 is an investigational CDH17-targeting ADC developed using Mabwell's proprietary IDDC™ platform. Its highly optimized structure integrates three key elements: - Mab0727: A highly specific CDH17 monoclonal antibody with rapid int
- 김갑성 기자
- 2025-10-14 20:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-19_SUN
- 내면의 조화를 발견하세요: '원더풀 인도네시아 웰니스 페스티벌 2025' 개최 01:50
- 제2회 마나르 아부다비 출품 작가 명단 공개 00:48
- 중국-피지 어업 협력, 섬나라 경제 활력 끌어올리다 00:00
2025-10-18_SAT
- The 6th International Ancient Capitals Forum Kicks off in Luoyang, Focusing on the Sustainable Development of Ancient Capitals 23:08
- Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO 22:46
- China's Sichuan Extends Cultural Tourism Invitations at Global Landmarks 21:20
- Manulife Hong Kong and JUST FEEL Promote Emotional Well-Being with City's First "My Flag Day" 16:23
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 19일 03시 20분